Belantamab mafodotin induces immunogenic cell death within 24 h post-administration in newly diagnosed multiple myeloma patients

Am J Hematol. 2023 Mar;98(3):E65-E67. doi: 10.1002/ajh.26823. Epub 2022 Dec 30.

Affiliations

¹ Department of Biology, School of Science, National and Kapodistrian University of Athens, Athens, Greece.
² Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.

PMID: 36565455
DOI: 10.1002/ajh.26823

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal, Humanized
Humans
Immunogenic Cell Death*
Multiple Myeloma* / drug therapy

Substances

belantamab mafodotin
Antibodies, Monoclonal, Humanized